同为GLP-1受体激动剂，为何药理表现不同？
2型糖尿病、肥胖及相关代谢性疾病均涉及葡萄糖稳态、胰岛内分泌、摄食和能量平衡异常。GLP-1R能够同时调节胰岛素分泌、胰高血糖素、胃排空和摄食行为，因此成为重要的代谢调控靶点。司美格鲁肽、利拉鲁肽、艾塞那肽、利西拉肽、度拉糖肽以及非肽小分子虽然均可激活GLP-1R，但不同的分子结构、长效化方式和体内暴露模式会改变受体刺激持续时间及各项生理作用的相对贡献，最终形成不同的药理表现。 ...
主题
GLP-1R
用于检测、定量和定位抗原与抗体的技术——ELISA、免疫印迹、免疫组化与流式细胞术。以下是我们知识库中标注该主题的实验方案、常见问题与技术文章。
8 项资源 · 实验方案、常见问题与文章
Why Do GLP-1 Receptor Agonists Show Different Pharmacological Profiles Despite Targeting the Same Receptor?
Type 2 diabetes, obesity, and related metabolic diseases all involve abnormalities in glucose homeostasis, pancreatic endocrine function, food intake, and energy balance. GLP-1R can simultaneously regulate insulin secretion, glucagon, gastric emptying, and feeding behavior and has therefore ...
Molecular Mechanisms, Biomarker Value, and Advances in Targeted Therapy for Core Pathological Targets in Alzheimer’s Disease
Alzheimer’s disease is jointly driven by Aβ deposition, Tau abnormalities, neuroinflammation, disrupted lipid metabolism, and synaptic injury. Defining the core targets at different pathological stages provides the basis for disease stratification, therapeutic monitoring, and the design of ...
阿尔茨海默病核心病理靶点的分子机制、生物标志物价值与靶向治疗进展
阿尔茨海默病由Aβ沉积、Tau异常、神经炎症、脂质代谢紊乱和突触损伤共同驱动。明确不同病理阶段的核心靶点，是疾病分层、疗效监测和联合治疗设计的基础。
GLP-1R、GIPR与GCGR在肥胖症和2型糖尿病代谢调控及多受体激动剂治疗中的作用
GLP-1R、GIPR与GCGR共同调节胰岛激素分泌、肝糖输出、摄食行为和能量代谢。多受体激动剂通过平衡降糖、食欲抑制与能量消耗作用，提高肥胖症和2型糖尿病的综合代谢干预效果。
Roles of GLP-1R, GIPR, and GCGR in Metabolic Regulation of Obesity and Type 2 Diabetes and in Multi-Receptor Agonist Therapy
GLP-1R, GIPR, and GCGR jointly regulate pancreatic hormone secretion, hepatic glucose output, feeding behavior, and energy metabolism. Multi-receptor agonists improve the overall metabolic treatment of obesity and type 2 diabetes by balancing glucose-lowering effects, appetite suppression, and ...
Pathogenesis, Therapeutic Targets, and Drug Development for Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH)
Metabolic dysfunction-associated steatohepatitis is jointly driven by hepatic fat accumulation, lipotoxicity, insulin resistance, inflammation, and fibrosis. Targeting lipid metabolism, nuclear receptors, incretin pathways, and FGF signaling has become a major direction in drug development.
代谢功能障碍相关脂肪性肝炎（MASH/NASH）的 发病机制、治疗靶点与药物开发
代谢功能障碍相关脂肪性肝炎由肝脂肪沉积、脂毒性、胰岛素抵抗、炎症和纤维化共同驱动。靶向脂质代谢、核受体、肠促胰素及FGF信号已成为药物开发的主要方向。
相关主题
常与免疫学实验一起研究的技术。
危险品化学品经营许可证（带存储）